Rare Diseases and Orphan Drugs

Biography

Thomas C Chen has founded NEONC Technologies, Inc., in 2008 and serves as its Chairman, Chief Executive Officer and Chief Scientific Officer. He is an Executive Director at Cognos Therapeutics Inc., Co-Founder of Pharmaco-Kinesis Corporation and serves as its Chief Oncology Officer. He serves as a Scientific Advisor, Scientific Collaborator at Tocagen Inc. He serves as an Associate Professor of Neurological Surgery and Pathology at the University of Southern California (USC), Principal Investigator of an Independent Laboratory and Head of the Glioma Research Group at USC. He also serves as the Director of Surgical Neuro-Oncology at USC. He is a Member of Neurological Board, Member of Clinical Advisory Board at Magnetecs Corporation. He is a Physician and a board certified Neurosurgeon. He holds an MD from the University of California San Francisco, completed his Neurological Surgery Residency and PhD in Pathobiology at the University of Southern California. He has obtained Fellowship training in Spinal Surgery from the Medical College of Wisconsin and was graduated from the University of Illinois at Urbana-Champaign. He holds a Bronze Tablet Honors from University of Illinois at Urbana-Champaign and was inducted into the Phi Beta Kappa national academic honor society.

Abstract

Abstract : Neo212: a new drug for temozolomide resistant malignant gliomas